A CE-marked in vitro diagnostic test that predicts progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia using mitochondrial DNA epigenetic biomarkers. The test combines Next Generation Sequencing and Machine Learning analysis of blood biomarkers with ApoE genotype and age asses...
Manufactured by
Sant Feliu de Llobregat (Barcelona), Spain
ADmit Therapeutics, S.L. is a company that has developed the MAP-AD® Test for the early detection of Alzheimers dementia and is currently in the commercialization stage. Alzheimers Disease (AD) is a devastating process for patients and their families and a threat to public health systems in both developed and emerging countries. It is an unmet medical need. It is estimated that more than 47 million people worldwide are suffering this disease, and that the incidence will increase considerably in the coming years due to the increase in life expectancy (130 million patients in 2050). Currently, there is an infradiagnosis of AD cases (mostly in the mild stage), and it is usually done in the moderate stage and with a delay of 12-24 months after the onset of symptoms. There is no any IVD implemented in clinical practice to predict progression to Alzheimers dementia in patients with Mild Cognitive Impairment. Our IVD represents the determination of a number of biomarkers not related to either β-amyloid or tau in a blood sample. Our value proposition is based on an epigenetic analysis covering a large number of methylcytosines using next-generation sequencing techniques. Our proprietary biomarkers combined with the age, the ApoE genotype and the CDR-SOB represent a very useful tool for the prognosis of progression to Alzheimers dementia in Mild Cognitive Impairment patients. This cutting-edge technology provides a comprehensive analysis of the patient.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
Origin Biotechnology Co., Ltd.
Taiwan · 2 relevant products
BioChain (Beijing) Science & Technology. Inc.
China · 3 relevant products
GENERI BIOTECH s.r.o.
Czech Republic · 3 relevant products
Fujirebio Diagnostics,Inc.
China · 7 relevant products
Lansion Biotechnology Co., Ltd.
China · 2 relevant products
GenSure Biotech Inc.
China · 2 relevant products
Abbott
United States · 2 relevant products
Chongqing Kangjuquanhong Biotechnology Co.,Ltd.
China · 2 relevant products
Eone-Diagnomics Genome Center
South Korea · 2 relevant products
POCBio (Nexlab Co., Ltd.)
China · 1 relevant product
46 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →6 more sourcing countries available
Get free access to all sourcing countries identified for this product.
See all countries →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
12 of 100 closest product alternatives
Origin Biotechnology Co., Ltd. · Taiwan
A diagnostic test for the assessment and diagnosis of dementia in elderly patients using molecular biomarkers.
BioChain (Beijing) Science & Technology. Inc. · China
Diagnostic test for early detection of cognitive impairment and neurodegenerative disease risk. This biomarker-based test supports early intervention strategies for age-related cognitive disorders. The product aligns with research collaborations in epigenetic disease markers.
GENERI BIOTECH s.r.o. · Czech Republic
CE IVD real-time PCR kit for apolipoprotein E genotyping in human genomic DNA. Enables detection of APOE polymorphisms relevant to cardiovascular and neurological disease risk assessment.
Fujirebio Diagnostics,Inc. · China
A cerebrospinal fluid detection test for Alzheimer's disease core biomarkers that provides enhanced sensitivity and more accurate results. This product targets the pathological hallmarks of Alzheimer's disease.
Lansion Biotechnology Co., Ltd. · China
Dry fluorescence immunoassay test kit for Alzheimer disease-associated protein detection. Enables rapid neurodegenerative disease screening.
GenSure Biotech Inc. · China
Diagnostic test kit for measurement of biomarkers associated with cerebrovascular disease and stroke risk. Facilitates assessment of neurological and cerebrovascular health status.
Abbott · United States
Mild traumatic brain injury biomarker diagnostic test designed to improve emergency department care and clinical decision-making through rapid, accurate diagnosis.
BioChain (Beijing) Science & Technology. Inc. · China
Epigenetic-based diagnostic test for early detection of cerebrovascular disease and stroke risk. Developed in collaboration with Beijing Tiantan Hospital, this test supports stroke prevention initiatives. The product integrates findings from a large-scale stroke cohort study.
Chongqing Kangjuquanhong Biotechnology Co.,Ltd. · China
A diagnostic test kit for measuring β-amyloid protein 1-42 using magnetic microparticle chemiluminescence immunoassay method. Applied in dementia assessment.
Eone-Diagnomics Genome Center · South Korea
A genetic risk prediction test that assesses hereditary susceptibility to major cancers, general diseases, and ophthalmological conditions. It enables early personalized management and health planning based on genetic risk factors.
POCBio (Nexlab Co., Ltd.) · China
A diagnostic test for detecting cardiac markers. This product is used for cardiac health assessment and monitoring.
Singlera GENOMICS (SHANGHAI) Ltd. · China
A specialized molecular diagnostic test for early detection and risk assessment of pancreatic cancer using DNA methylation technology. Supports early diagnosis of this highly aggressive malignancy.
88 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products